Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. Paradoxically, a majority of CVID patients have non-infectious inflammatory and autoimmune complications, associated with systemic immune activation. Our aim was to explore if HDL, known to have anti-inflammatory properties, had impaired function in CVID patients and thereby contributed to their inflammatory phenotype. We found reduced HDL cholesterol levels in plasma of CVID patients compared to healthy controls, particularly in patients with inflammatory and autoimmune complications, correlating negatively with inflammatory markers CRP and sCD25. Reverse cholesterol transport capacity testing showed reduced serum acceptance capacity for cholesterol in CVID patients with inflammatory and autoimmune complications. They also had reduced cholesterol efflux capacity from macrophages to serum and decreased expression of ATP-binding cassette transporter ABCA1. Human HDL suppressed TLR2-induced TNF release less in blood mononuclear cells from CVID patients, associated with decreased expression of transcriptional factor ATF3. Our data suggest a link between impaired HDL function and systemic inflammation in CVID patients, particularly in those with autoimmune and inflammatory complications. This identifies HDL as a novel therapeutic target in CVID as well as other more common conditions characterized by sterile inflammation or autoimmunity.

[1]  Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency , 2019, Scientific Reports.

[2]  K. Liao,et al.  The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis , 2015, Journal of the American Heart Association.

[3]  K. Rye,et al.  HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. , 2015, Circulation research.

[4]  B. Lambrecht,et al.  Genes associated with common variable immunodeficiency: one diagnosis to rule them all? , 2016, Journal of Medical Genetics.

[5]  P. Bromberg.  Structure-Function Relationships , 1999 .

[6]  K. Mullen,et al.  Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. , 2010, Journal of clinical lipidology.

[7]  J. Heinecke.  Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL. , 2015, Circulation research.

[8]  I. Vořechovský,et al.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID) , 2000, Clinical and experimental immunology.

[9]  É. Oksenhendler,et al.  Clinical picture and treatment of 2212 patients with common variable immunodeficiency. , 2014, The Journal of allergy and clinical immunology.

[10]  C. Cunningham-Rundles.  Common variable immune deficiency: Dissection of the variable , 2018, Immunological reviews.

[11]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[12]  M. Vlková,et al.  Altered Serum Cytokine Signature in Common Variable Immunodeficiency , 2014, Journal of Clinical Immunology.

[13]  S. Taylor-Robinson,et al.  Serum Metabolic Profiling in Inflammatory Bowel Disease , 2012, Digestive Diseases and Sciences.

[14]  A. Morgun,et al.  CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon-driven inflammation possibly related to the presence of a pathobiont. , 2018, Clinical immunology.

[15]  S. Pillemer,et al.  Serum lipid levels in Sjögren's syndrome. , 2006, Rheumatology.

[16]  E. Latz,et al.  High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3 , 2013, Nature Immunology.

[17]  Sudhir Gupta,et al.  Common variable immunodeficiency associated with microdeletion of chromosome 1q42.1-q42.3 and inositol 1,4,5-trisphosphate kinase B (ITPKB) deficiency , 2016, Clinical & translational immunology.

[18]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[19]  M. Reilly,et al.  Inflammation modulates human HDL composition and function in vivo. , 2012, Atherosclerosis.

[20]  T. Karlsen,et al.  Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation , 2016, Mucosal Immunology.

[21]  C. Cunningham-Rundles,et al.  Morbidity and mortality in common variable immune deficiency over 4 decades. , 2012, Blood.

[22]  E. López-Granados,et al.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. , 2010, The Journal of allergy and clinical immunology.

[23]  S. Frøland,et al.  Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences. , 1996, Blood.

[24]  A. Kontush,et al.  Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.

[25]  Ş. Arslan,et al.  Accelerated atherosclerosis in patients with common variable immunodeficiency: Is it overlooked or absent? , 2015, Medical hypotheses.

[26]  S. Hix,et al.  Higher Cardiovascular Risk in Common Variable Immunodeficiency and X-Linked Agammaglobulinaemia Patients , 2015, Annals of Nutrition and Metabolism.

[27]  Y. Marcel,et al.  Apolipoprotein A-I: structure-function relationships. , 2000, Journal of lipid research.

[28]  T. Marquès-Bonet,et al.  Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond , 2018, Front. Immunol..

[29]  Pan‐Chyr Yang,et al.  Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis* , 2005, Critical care medicine.

[30]  T. Karlsen,et al.  A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency , 2016, The American Journal of Gastroenterology.

[31]  D. Gevers,et al.  The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids , 2015, Circulation research.

[32]  M. Vlková,et al.  Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia , 2012, Clinical and experimental immunology.

[33]  K. Moore,et al.  Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis , 2018, Circulation.

[34]  L. Gordon,et al.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. , 2015, Cancer treatment and research.

[35]  L. Klareskog,et al.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[36]  S. Reddy,et al.  Structure and function of HDL mimetics. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[37]  V. D’Agati,et al.  Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity. , 2017, Cell metabolism.

[38]  B. Fevang,et al.  Autoimmunity and Inflammation in CVID: a Possible Crosstalk between Immune Activation, Gut Microbiota, and Epigenetic Modifications , 2018, Journal of Clinical Immunology.

[39]  B. Fevang,et al.  Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo , 2007, Clinical and experimental immunology.

[40]  Anne-Kathrin Kienzler,et al.  The role of genomics in common variable immunodeficiency disorders , 2017, Clinical and experimental immunology.